HOME >> BIOLOGY >> NEWS
Mouse model reveals that oncoprotein induces abnormal preleukemic blood cell progenitors

Scientists have developed a novel mouse model for leukemia that reveals critical information about the mechanisms involved in leukemia progression and provides a model system for evaluation of new drugs for treatment of leukemia. The research, published in the January issue of Cancer Cell, utilizes a technique that allows induction and study of a key oncoprotein in adult mice. Previously, it was difficult to investigate this oncoprotein in the mouse, as the expression of this gene is associated with embryonic lethality, or death of the developing mouse in utero.

Acute myeloid leukemia (AML) can arise from genetic alterations in the bone marrow cells that give rise to blood cells. One fusion oncoprotein that is present in about 12% of human AML cases and is known to interfere with the process of normal blood cell development is called CBFB-SMMHC. Thus far, this protein has been very difficult to study in mouse models, as its expression causes embryonic lethality. Dr. Lucio H. Castilla from the Program in Gene Function and Expression at the University of Massachusetts Medical School and colleagues created a conditional mouse model to analyze the preleukemic effects of CBFB-SMMHC on blood cell production and AML development in adult mice. The mouse model enabled the scientists to selectively turn on expression of CBFB-SMMHC in adult mice, thereby avoiding embryonic lethality of expression of this gene, and then study the effects.

The researchers found that CBFB-SMMHC induction was associated with a reduction of immature blood cells in the bone marrow and with the appearance of abnormal progenitor cells that are leukemic precursors. Mice expressing CBFB-SMMHC developed AML with a median latency of approximately five months, with the time of disease onset varying with the number of abnormal cells in the bone marrow. Interestingly, additional studies showed that the blood stem cell precursors that expressed CBFB-SMMHC were maintained at normal levels for l
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
17-Jan-2006


Page: 1 2

Related biology news :

1. Mouse model advances understanding of synovial sarcoma
2. Mouse FH knockout resembles human renal cell cancer
3. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
4. Mouse model underestimates the critical role of Tyk2 in human immune system
5. Mouse DNA to aid biomedical research
6. Mouse strain with gene stutter will help leukemia research
7. Knockout Mouse Project
8. NIH launches Knockout Mouse Project
9. Mouse mimics chronic leukemia, will aid drug development
10. Mouse, frog and bird put Snail and Slug to different uses
11. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk

Post Your Comments:
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... JOLLA, Calif. , Jan. 30, 2015  It ... the great power and potential for genomic science as ... aid in disease prevention and treatment.  I was honored ... potential new, government-funded precision medicine program. ... advancing the science of genomics—from the first sequenced genome ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015 The healthcare ... this ever-changing arena, Frost & Sullivan will host its ... Sullivan Executive MindXchange , March 8 to 10, at the ... Diego, Calif. This event is a ... healthcare leaders to discuss industry disruptions and how to succeed ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which takes ... Morial Convention Center in New Orleans, Louisiana, will ... 2015) displaying products and services used by the ... The Exposition will offer the latest innovations in ... chemistry; drug discovery; nanotechnology; life sciences to include ...
(Date:2/26/2015)... February 26, 2015 Innovation is ... emerging from unexpected parts of the world and ... From agriculture to manufacturing to health care, disruption ... environmental realities and socio-political trends shake the foundations ... key ingredient for CEOs to survive the next ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
Cached News: